Liang Min, Luo Ning, Chen Mafeng, Chen Chunna, Singh Shivank, Singh Shantanu, Tan Shifan
Department of Respiratory and Critical Care Medicine, Maoming People's Hospital, Maoming, China.
Department of Otolaryngology, Maoming People's Hospital, Maoming, China.
Infect Dis Ther. 2021 Sep;10(3):1267-1285. doi: 10.1007/s40121-021-00447-1. Epub 2021 May 3.
The coronavirus disease 2019 (COVID-19) was defined as a species of beta coronavirus causing atypical respiratory disease in humans. The COVID-19 pandemic has resulted in an unprecedented health and economic crisis worldwide. Little is known about the specifics of its influence on people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA). In this study, we aim to investigate the prevalence and mortality in PLWHA co-infected with COVID-19.
The databases PUBMED, EMBASE, BioRxiv, and medRxiv were searched up to 9 March 2021 to explore the prevalence and mortality rate of COVID-19 in PLWHA. Cohort studies and case series meeting the inclusion criteria were included in this review.
We identified 14 eligible studies, 9 of which were cohort and 5 were case series. A total of 203,761 patients with COVID-19 were identified (7718 PLWHA vs. 196,043 non-PLWHA). Meta-analyses estimated the prevalence and mortality rate of COVID-19 in PLWHA was 0.774% [95% confidence interval (CI) 0.00393-0.01517] and 8.814% (95% CI 0.05766-0.13245) respectively. COVID-19 co-infected PLWHA do not seem to be associated with higher mortality, as compared to non-PLWHA [relative risk (RR) 0.96 (95% CI 0.88-1.06)]. The presence of comorbidities such as diabetes mellitus, RR 5.2 (95% CI 4.25-6.36), hypertension and chronic cardiac disease, RR 4.2 (95% CI 1.09-16.10), and chronic kidney disease, RR 8.43 (95% CI 5.49-12.93) were associated with an increased mortality in COVID-19 co-infected PLWHA.
The estimated prevalence and mortality rate of COVID-19 in PLWHA were 0.774% and 8.814%, respectively. Since most of the included studies used unmatched populations, comparisons between PLWHA and non-PLWHA should be interpreted with caution. Further investigations are needed for a more comprehensive understanding of the relationship between cluster of differentiation 4 cell count, HIV viral load, antiretroviral therapy, and COVID-19 related prognosis in PLWHA.
2019年冠状病毒病(COVID-19)被定义为一种可导致人类非典型呼吸道疾病的β冠状病毒。COVID-19大流行在全球范围内引发了前所未有的健康和经济危机。关于其对人类免疫缺陷病毒(HIV)/获得性免疫缺陷综合征(AIDS)患者(PLWHA)影响的具体情况,人们知之甚少。在本研究中,我们旨在调查合并感染COVID-19的PLWHA的患病率和死亡率。
截至2021年3月9日,对数据库PUBMED、EMBASE、BioRxiv和medRxiv进行检索,以探究PLWHA中COVID-19的患病率和死亡率。符合纳入标准的队列研究和病例系列纳入本综述。
我们确定了14项符合条件的研究,其中9项为队列研究,5项为病例系列。共确定了203,761例COVID-19患者(7718例PLWHA与196,043例非PLWHA)。荟萃分析估计,PLWHA中COVID-19的患病率和死亡率分别为0.774% [95%置信区间(CI)0.00393 - 0.01517]和8.814%(95% CI 0.05766 - 0.13245)。与非PLWHA相比,合并感染COVID-19的PLWHA似乎与更高的死亡率无关[相对风险(RR)0.96(95% CI 0.88 - 1.06)]。合并症如糖尿病(RR 5.2,95% CI 4.25 - 6.36)、高血压和慢性心脏病(RR 4.2,95% CI 1.09 - 16.10)以及慢性肾脏病(RR 8.43,95% CI 5.49 - 12.93)与合并感染COVID-19的PLWHA死亡率增加相关。
PLWHA中COVID-19的估计患病率和死亡率分别为0.